Lead Product(s) : MT1988
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Forster Foundation
Deal Size : $1.2 million
Deal Type : Financing
Monument Therapeutics Secures £1M for Schizophrenia Program Growth
Details : The funding will support the clinical development of MT1988, a novel fixed-dose combination drug for the treatment of cognitive impairment associated with schizophrenia.
Product Name : MT1988
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 15, 2024
Lead Product(s) : MT1988
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Forster Foundation
Deal Size : $1.2 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : MiHKAL GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
Details : The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 14, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : MiHKAL GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : 4-Chlorokynurenine,Probenecid
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : VistaGen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
VistaGen and Nuformix agree to develop cocrystalline forms of AV-101
Details : Under this agreement, VistaGen and Nuformix initially will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual...
Product Name : AV-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2020
Lead Product(s) : 4-Chlorokynurenine,Probenecid
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : VistaGen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Psilocybine,LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.
Product Name : ELE-Psilo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 03, 2020
Lead Product(s) : Psilocybine,LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable